Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan T., Jakubowiak, Andrzej, Dingli, David, Cornell, Robert F., Hofmeister, Craig C., Siegel, David, Berdeja, Jesus G., Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol Ann, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay K., Richter, Joshua, Abonour, Rafat, Parker, Terri L., Yee, Andrew J., Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja C., Mohty, Mohamad, Choquet, Sylvain, Unger, T. J., Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Dimopoulos, Meletios Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449872/
https://www.ncbi.nlm.nih.gov/pubmed/32094461
http://dx.doi.org/10.1038/s41375-020-0756-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449872/
https://www.ncbi.nlm.nih.gov/pubmed/32094461
http://dx.doi.org/10.1038/s41375-020-0756-6

Ejemplares similares